ImmunityBio Inc(IBRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.97 | Insider Own | 62.16% | Shs Outstand | 1.05B | Perf Week | -7.24% |
| Market Cap | 8.28B | Forward P/E | - | EPS next Y | 88.18% | Insider Trans | -0.08% | Shs Float | 401.0M | Perf Month | -7.46% |
| Enterprise Value | 9.15B | PEG | - | EPS next Q | -0.07 | Inst Own | 19.33% | Short Float | 30.94% | Perf Quarter | 12.05% |
| Income | -0.99B | P/S | 49.93 | EPS this Y | -152.63% | Inst Trans | 5.47% | Short Ratio | 10.76 | Perf Half Y | 7.13% |
| Sales | 0.17B | P/B | - | EPS next 5Y | - | ROA | -192.58% | Short Interest | 124.09M | Perf YTD | 294.44% |
| Book/sh | -0.99 | P/C | 23.16 | EPS past 3/5Y | 28.42% 15.6% | ROE | - | 52W High | -37.17% ($12.43) | Perf Year | 216.19% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | 678.62% 299.74% | ROIC | -569.64% | 52W Low | 300.51% ($1.95) | Perf 3Y | 280.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -110.7% | Gross Margin | 89.33% | Volatility(W/M) | 7.73% 8.35% | Perf 5Y | -1.88% |
| Dividend TTM | - | EV/Sales | 55.19 | Sales Y/Y TTM | 192.92% | Oper. Margin | -151.88% | ATR (14) | 0.7 | Perf 10Y | 22.22% |
| Dividend Ex-Date | - | Quick Ratio | 5.7 | EPS Q/Q | -110.56% | Profit Margin | -598.56% | RSI (14) | 37.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.72 | Sales Q/Q | 93.91% | SMA20 | -16.58% ($9.36) | Beta | 0.17 | Target Price | $14.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/4 | SMA50 | -9.71% ($8.65) | Rel Volume | 0.96 | Prev Close | $8.22 |
| Employees | 691 | LT Debt/Eq | - | EPS/Sales Surpr. | -175% 3.1% | SMA200 | 0.34% ($7.78) | Avg Volume(3M) | 11.54M | Price | $7.81 |
| IPO | 2015/7/28 | Option/Short | Yes/Yes | Trades | 31257 | Volume | 11,049,529 | Change | -4.99% |
🧬 A US biotech company that develops and sells immuno-oncology therapies. It has secured approval and is selling an immunotherapy for bladder cancer in the U.S. and other markets, driving rapid revenue growth, and holds a broad pipeline expanding into indications such as lung cancer and pancreatic cancer, making it a healthcare stock.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded about as much as usual. That is 96% of its average volume.
IBRX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -152.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,993. Peers typically go for $1,575.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -1.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
30.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #34 of 594 in the industry
Based on market cap of $8B.
FAQ
What kind of company is IBRX?
IBRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IBRX?
The market cap of IBRX is approximately $8.3B, ranking 1,016 within its sector.
What is the 52-week high and low for IBRX?
IBRX has recorded a 52-week high of $12.43 and a low of $1.95.
